3rd ESTRO Forum 2015 S761 Table 1 . Comparison of D4 γ results, DC γ and DC DD for lung plans with and without density override (DO) in the body or lung volume.
Purpose/Objective: The new commercial thermal neutron device (TNRD) has a good response with directionality in a pure neutron beam [1] . In addition, good coincidence with TLD detectors was found for peripheral neutron dose estimation in-phantom [2] . Nevertheless, further experiments have shown that TNRD is not completely reliable in some special clinical conditions, due to photon contribution. The aim of this work is the knowledge of uncertainties related to photon presence under different irradiation conditions, especially angle incidence influences at different field-edge distances. This will not only verify the goodness of TNRD measurements due to a possible compensation, but to find a possible correction to improve peripheral neutron doses estimation. Materials and Methods: TNRD detector is based on a pair of commercial photodiodes, and allows the measurement of thermal neutron fluences under an intense photon background [1] . However in the case of an in important photon presence, intrinsic differences among diodes make TNRD signal to be over or underestimated, due to their relative position with respect to the beam incidence. This could be a consequence of 'shadow' effect, from one diode to the other, as the reading is obtained by the subtraction of both signals (the one of the sensitized to neutrons and the normal one). Six gantry angle incidences (0º, 45º, 135º, 180º, 225º and 315º) were measured in 6 and 15 MV for two different field-edge detector distances (10 and 25 cm, corresponding to an approx. dose rate 3.53 and 1.21 cGy/min). A Primus Siemens linac using a 40x10 cm 2 field was employed with TNRD detectors inserted in the middle of two layers of 4 cm polyethylene. Results: The table shows TNRD readings at 6 MV (photon signal) and neutron component from 15 MV (subtraction of 15 MV and 6 MV readings). Photon influence in TNRD neutron readings are up to 50% for 315º and 135º for 10 cm. However if we consider the accumulated readings among the whole arc, total photon component is compensated and reduced to 9.3% or 6.7% depending on distance to field-edge. The figure shows the compensation of photon component for complementary gantry angles. treatment plan is made possible by a treatment planning algorithm that simultaneously changes three parameters during treatment, i) rotation speed of the gantry ii) shape of the treatment aperture using the movement of multileaf collimator leaves, and iii) delivery dose rate. Due to the complexity of treatment planning and delivery there is a necessity of dosimetric verification of a RapidArc plan. Generally, this verification is carried out using ion chambers, diodes, films, 2D array & other tools which is cumulative in nature and also time consuming. In this study we created a RapidArc QA plan using Eclipse-10 (Varian medical Systems) treatment planning system and carried out the dosimetry with an amorphous silicon electronic portal imaging device (a-Si EPID). The RA delivers a precisely sculpted 3D dose distribution with 360-degree rotation of the linear accelerator gantry, and hence the conventional cumulative dosimetry based QA tools may miss instant deviations from the planned delivery at specific gantry angles or control points. To overcome this problem, we divided a counter clockwise (CCW) and clockwise (CW) Rapid Arc of 358' delivery into 7 small sub arcs of 50´ each in Eclipse treatment planning system, and measured these sub arcs using amorphous silicon electronic portal imaging device (a-Si EPID). We analysed these sub arcs and composite arc EPID dose fluence using the portal dosimetry software. We also analysed the cumulative dose image generated by summation of all sub arcs. A total of 20 Rapid Arc Patient planning were analysed for this study. Results: The gamma index (DTA: 3.0 mm Tolerance: 3.0 %) evaluated by us indicated good correlation between predicted and acquired EPID images for a complete arc with a few differences in high gradient areas. In the case of sub arc QA, it was found that gamma index was violated in a two patients with one sub Arc for Area Gamma < 1.0 is 65.3% and 88.9 %, where tolerance is 95.0 %. Interestingly, for these patients the cumulative QA results showed no violation. Conclusions: It is, therefore, concluded that QA of RA plans based on sub arcs methods should be part of the overall QA process. Specially for complex treatment plan where we are trying to save critical organ vary close proximity of target using Rapid Arc. So we found the a-Si EPID -based pretreatment RA verification method to be a good quality assurance (QA) procedure for the purpose.
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Experience using a commercial software for patient in-vivo and pre-treatment quality assurance L. Reversi 1 , C. ), a patient QA software. Materials and Methods: DC allows for both pre-treatment QA and in vivo dose verification, using the EPID measured fluence of the treatment fields to reconstruct the dose distribution in the CT planning model of the patient. First tests were performed on the IBA 'I'm RT' phantom to assess DC performances in the steps of entrance fluence estimation and dose calculation. The central cubic insert was filled in three different ways: homogeneously with RW3 slabs (phantom H) or replacing the central slabs with air (phantom A) or bone inserts (phantom B). The accuracy of entrance fluence estimation independently of the irradiated object was evaluated acquiring EPID data in vivo and pre treatment on the three phantoms for different square field sizes (FS) and then evaluating the isocenter dose in phantom H with DC. The global accuracy was assessed by comparing OFs and PDDs evaluated with TPS with that reconstructed by DC. Finally, DC was run on pre-treatment and in-vivo images of 15 patients: 1) 7 IMRT prostate cases, 2) 3 abdominal VMAT cases, 3) 5 head VMAT cases. Gamma analysis (3%, 3mm) was used to compare measured with calculated dose distribution. Results: Average absolute differences of isocenter doses in phantom H obtained with DC from in vivo measurement with respect to that obtained from pre treatment measurement were 0.43%, 0.82% and 0.92% for B, H and A phantoms respectively. Maximum deviation (1.75%) was observed for phantom A and 3.2 cm FS. Pre treatment measurements produced relative differences on OFs between 0.01/0.53%. H and B phantoms gave similar values (-0.48/0.92%, and 0.70/0.80% respectively). Due to the use of a pencil beam algorithm (PB), higher differences were found in phantom A, especially for small fields (64.2% for 2.4 cm FS vs -2.1% for 15.2 cm FS). The effects of the PB were also observed on the PDDs. For H and B phantoms, the percent difference remained within 1/1.5% at all depths (exception for the buildup region) for the 3.2 and 10.4 cm FSs respectively. For the A phantom, DC overestimated the dose up to 12% and 110% in the air thickness for the 10.4 cm and 2.4 cm field size respectively. Patients results are summarised in table 1.For each patient the value of the dose difference at the isocenter, PTV and patient gamma passing rates are reported. The in vivo values are the average values of the treatment sessions acquired. The worst result has been obtained for PTV pre and in vivo head treatment where the DC algorithm fails due to air in the nasal cavity.
